SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors await clarity on the FDA's regulatory path for deramiocel, with community members actively discussing the potential for a PDUFA extension and a pivot to an upper-limb function indication. Bullish sentiment remains focused on the drug's therapeutic potential for DMD patients and the prospect of a short squeeze, while skeptics emphasize regulatory hurdles and the risks associated with the extended review timeline.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors weigh conflicting catalysts, including reports of upcoming hardware price hikes and new strategic investments against the backdrop of highly anticipated quarterly earnings. Community sentiment remains deeply divided, with some traders expecting a blowout performance to fuel a rally, while others fear a "sell-the-news" reaction following a week of bearish price action and macroeconomic uncertainty.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as investors aggressively monitor the pivotal REGAL Phase 3 trial for updates on the 80th clinical event, which acts as a key catalyst for potential final efficacy analysis. The community is sharply divided between bullish expectations for a curative leukemia treatment and skeptical debate regarding trial transparency, patient population size, and market rumors.

CF Acquisition Corp. VI operates as a blank check company. It focuses on the search of companies in the financial services, healthcare, real estate services, technology and software industries. The company was founded on April 17, 2020 and is headquartered in New York, NY.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending after announcing a landmark $13.7 billion contract to supply GPU cloud services, sparking massive community discussion regarding a potential short squeeze and long-term rerating. Investors are actively debating the implications of the deal's unnamed customer, performance-based warrants, and the company's path to scaling its data center infrastructure.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors react to a significant share price decline, with the community actively debating whether the current pullback is a strategic buying opportunity or a signal of deeper institutional distrust in management's execution. Discussion remains polarized between those citing strong QNX partnerships as long-term catalysts and those frustrated by delayed product milestones and recent insider selling.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is generating significant buzz as it nears the psychological $80,000 level, with the community actively debating whether this momentum indicates a sustained bull run or a precursor to a sharp liquidation. Traders are closely monitoring upcoming Treasury bond announcements and potential regulatory shifts as key catalysts that could either fuel further upside or trigger a volatile correction.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is trending as investors weigh strong delivery numbers and the upcoming global launch of its MONA L03 model against broader concerns about the Chinese EV sector. The community is actively debating the company's long-term potential, specifically focusing on its robotics division and its ability to maintain growth through technological innovation.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending as the stock benefits from a bullish Bitcoin environment and Strategy's announcement of a new $1.59 billion USD cash pool designed to increase corporate flexibility. Retail investors are actively debating the stock's future performance, focusing on a potential short squeeze and the impact of the company's aggressive share dilution strategies versus its massive Bitcoin treasury.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BitMine Immersion Technologies is trending as investors react to the company's ETH treasury expansion and share buyback initiatives, while the broader crypto sector experiences a bullish surge. Community discussion is heavily focused on the stock's sensitivity to Ethereum price movements, potential short squeezes, and debate over management's capital allocation strategies.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is facing intense volatility after receiving a Complete Response Letter from the FDA for its Hunter syndrome gene therapy, RGX-121, despite community arguments that the market is overreacting given the drug's safety profile and the company's broader pipeline potential. Investors are actively debating the regulatory path forward, the company's cash runway, and the ongoing transition in FDA leadership.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PHAT Well, the shenanigans continue…. Reasons to my knowledge, unknown but obviously I am missing something here. 

https://www.marketbeat.com/instant-alerts/filing-3496808-shares-in-phathom-pharmaceuticals-inc-phat-acquired-by-carlyle-group-inc-2026-08-18/

Paul Howard

E.C.

Pelle

Kevin

Luis C

Carlyle Group Inc. bought a new stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,496,808 shares of the company's stock, valued at approxi

MarketBeat

3,496,808 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by Carlyle Group Inc.

StockTwits for iOS

Phathom Pharmaceuticals Inc

 Well, the shenanigans continue…. Reasons to my knowledge, unknown but obviously I am missing something here. 



@Flyguy123 AQRs only marketable product is their long short (which is ass). My assumption would be theyre short

StockTwits For Android 

 AQRs only marketable product is their long short (which is ass). My assumption would be theyre short